Amedisys (AMED) Tops Q4 EPS by 5c

Amedisys (NASDAQ: AMED) reported Q4 EPS of $0.40, $0.05 better than the analyst estimate of $0.35. Revenue for the quarter came in at $337.3 million versus the consensus estimate of $322.01 million.

Earnings before interest, taxes, depreciation and amortization attributable to continuing operations (“EBITDA”) of $27.6 million compared to $22.9 million in 2014.

For earnings history and earnings-related data on Amedisys (AMED) click here.

You May Also Be Interested In

• EU proposes to curb Airbnb and short-term rentals amid housing shortage
• Barclays Downgrades Ipsen SA (IPN:FP) (IPSEF) to Underweight
• Prabhudas Lilladher Upgrades GE Vernova T&D India (GVTD:IN) to Buy (1)